
NanoPalm applies its delivery platform to co-develop therapeutics while maintaining an aligned, partner-centric business model.
NanoPalm's pLNP platform addresses key scientific and commercial challenges of conventional LNPs — helping partners advance novel therapies with greater confidence, speed, and regulatory readiness.
Ionizable lipid-free design reduces a key source of toxicity in conventional LNP systems.
Ligand-free self-targeting enables delivery to extra-hepatic tissues without active ligands.
Semi-solid patterned architecture improves stability and reduces cold-chain burden.
Differentiated IP landscape beyond crowded conventional LNP space, with co-IP pathways.
CMC-aligned manufacturing supports reproducibility, scalability, and regulatory readiness.
Every formulation tailored to your payload, target organ, route, and clinical objective.
Skip months of formulation. Get pre-designed, ready-to-use pLNP chips delivered to your bench — just add your payload and run.
Explore the chips →Put our platform to the test on your target. We co-run a focused pilot to prove delivery performance — fast, structured, and milestone-driven.
Explore Collaborations →Go all the way. We jointly develop your therapeutic asset end-to-end — shared IP, shared milestones, shared upside.
Explore More →A structured, milestone-driven co-development journey — from early feasibility to IND-enabling readiness.
Customized collaboration framework
Formulation report & initial data
Lead candidate & IP strategy
Preclinical data package
IND-enabling readiness package
pLNP Chips, pLNP formulations, preclinical data, co-IP potential
Scientific support, milestone tracking, regulatory documentation
Validated delivery system ready for clinical planning
Ionizable lipid-free, reduced cold-chain, expanded IP, CMC-ready
Explore how NanoPalm's pLNP platform can accelerate and de-risk your next therapeutic program.
Start a Partnership →